This study focuses on the comparative in vitro cytotoxicity of chelidonine and homochelidonine on human cancer and non-cancer cells. Both alkaloids produced a decrease in cellular growth in a dose-dependent manner exhibiting greater potency in cancer cells. The growth inhibitory effect was evidenced in both ovarian carcinoma A2780 and lung fibroblast MRC-5 cells by inducing G2 and mitotic phase cell cycle arrest. Results indicated that the extent of apoptosis induced by chelidonine and homochelidonine was correlated to sensitivity to the antiproliferative activity of the evaluated compounds. Western blotting suggested that the cellular toxicological mechanism of chelidonine is related to the differential upregulation of phospho-Chk2, p21
Greater Celandine, Chelidonium majus L. (Papaveraceae), is a valuable plant in Western herbalism. Various parts of the plant are used for the production of nutraceuticals and functional foods mitigating health problems, and in traditional Chinese medicine [1] . Crude extracts of C. majus (as well as purified compounds derived from it) exhibit a broad spectrum of bioactive properties with a potential for the protection of human health, such as antiinflammatory [2a] , antimicrobial [1] , cytotoxic, analgesic [2b, c], antioxidant [2d], antiulcer [2e], acetylcholinesterase-and butyrylcholinesterase-inhibitory [2f], and hepatoprotective activities [2g, h] . With ongoing research efforts to characterize the compounds behind the biological activity, Greater Celandine has been identified as a rich source of isoquinoline alkaloids with benzophenanthridine, protopine and protoberberine-type skeletons. The aerial parts of the plant contain between 0.5 and 1.5%, w/w, of alkaloids, while the roots contain between 2 and 3%, w/w [3] . Another evaluation of Greater Celandine roots documented up to 8%, w/w, of benzophenanthridine alkaloids [4] . Further phytochemical analysis revealed the presence of over 50 structurally different alkaloids, the main ones in the aerial parts of the plant being chelidonine, berberine and coptisine, while sanguinarine and chelerythrine were predominant in the roots [3,5a,b] . However, in spite of the progress so far, the use of Greater Celandine-derived pharmaceutical products still remains in preclinical development. Therefore, processed parts of the plant and tinctures from C. majus represent the main products currently obtainable on the market. In this regard, preferentially hydroethanolic extracts are used internally to stimulate the production of bile and pancreatic digestive enzymes. These attributes of C. majus extract are favorably exploited in a liquid polyherbal formulation with prokinetic action (STW 5) [6] . When applied topically, the extract has long been a popular remedy for the removal of warts and for healing skin affections [1] . Besides growing evidence of the versatile health benefits, including the previously stated hepatoprotective activity, an increasing number of studies have reported contradictory hepatotoxic effects following the consumption of C. majus extract either alone or in herbal preparations which contain C. majus extract as a component [7] . Toxicological investigations of multi-component extracts of C. majus are faced with the difficulties associated with interpreting combined toxicity, and thus more investigations are needed to consider the cytotoxic activity of pure compounds isolated therefrom. The scientific rationale for such an approach was reviewed by Colombo and Bosisio [8] . The authors compared the activity of C. majus extracts with their composition (major purified compounds) and concluded that alkaloids are mostly responsible for those activities.
In our previous work, we found that the C. majus alkaloids chelidonine and homochelidonine ( Figure 1 ) displayed significant cytotoxicity against a mini-panel of blood cancer cells. Human leukemic cells exposed to the alkaloids were arrested in the cell cycle and showed features of apoptosis, such as phosphatidylserine exposure, a loss of mitochondrial membrane potential and an increase in caspases -3/7, -8 and - 9 [2c] . All in all, C. majus alkaloids have a potential medicinal value. However, the integration of either C. majus herb or its active ingredients (alkaloids) into modern medical practice, besides the treatments of hematological malignancies, must take into account the interrelated issue of activity against cells simulating healthy human tissue. As part of our ongoing research on Greater Celandine alkaloids, we therefore aimed to screen the antiproliferative and cytotoxic activity of the C. majus dimethoxy analogues, chelidonine and homochelidonine, against selected human cancer and non-cancer cells. Apart from initial screening, we also investigated the mechanism underlying chelidonine-induced antiproliferative and cytotoxic activity. The study of their anticancer potential was also extended to cell cultures derived from solid tumors, non-cancer cells and the MAPK signaling cascade. 
Antiproliferative and cytotoxic effects of chelidonine and homochelidonine
First, chelidonine and homochelidonine were tested for their ability to inhibit cell proliferation using a mini-panel of human cancer (A2780, A549, HepG2, SK-BR-3 and MCF-7) as well as noncancer (MRC-5 and WI-38) cells. In the initial sets of experiments, cell proliferation was assessed by the sulforhodamine B assay. All cancer cell lines were affected by chelidonine exposure, although the various cell lines exhibited different sensitivities. Among the cell lines assayed, A2780, SK-BR-3 and A549 were most affected, resulting in a rapid and significant inhibition of cell proliferation at the evaluated concentrations. Chelidonine applied at 5 µM demonstrated the strongest inhibition on A2780 cell growth leading to relative growth of 17.6 ± 2.3% at 48 h and 6.3 ± 0.5% at 96 h compared with 0.1% DMSO vehicle-treated control (100.0 ± 5.8 %). Chelidonine exhibited modest antiproliferative activity against SK-BR-3 and A549 cells after both 48 and 96 h of treatment. The proliferation of SK-BR-3 and A549 cells in both evaluated intervals was considerably inhibited (>50% growth inhibition) at concentrations of 10 µM and 20 µM. HepG2 and MCF-7 cells were preferentially affected by chelidonine after a longer interval of exposure (96 h), where >50% growth inhibition was observed at concentrations ranging from 10 µM for HepG2 and 20 µM for MCF-7 cells. MRC-5 and WI-38 cell lines displayed the lowest susceptibility to chelidonine, with less than 50% inhibition of cell proliferation being observed at 20 µM over the whole treatment period. Homochelidonine also displayed a concentration and timedependent antiproliferative activity, although to a much lesser extent when compared with chelidonine. Proliferation of A2780 cells treated with homochelidonine was significantly affected (P ≤ 0.05) at 5 µM after 48 h of treatment (84.6 ± 3.5%) and at 10 µM after 96 h of treatment (12.5 ± 3.6%) in a dose-depended manner. Considering other cancer cells treated with homochelidonine, higher than 50% inhibition of cell growth was achieved in SK-BR-3, HepG2 and MCF-7 cells exposed to 20 µM for 96 h. Homochelidonine showed either inferior or comparable inactivity against MRC-5 and WI-38 fibroblasts in comparison with chelidonine. In fact, chelidonine was the most cytostatic compound to the cancer cell lines tested, with MRC-5 and WI-38 fibroblasts being the least affected. The relative growth inhibitory activities (%) measured by sulforhodamine B staining are plotted as bar graphs in Figure 2 .
For further evidence of antiproliferative activity, chelidonine and homochelidonine treatment was evaluated using an xCELLigence RTCA instrument, which allows the on-going monitoring of the effect of the compounds over a 72 h period. The addition of compounds (indicated as vertical lines in the histograms) rapidly reduced cancer cell numbers (expressed as normalized cell index) after 24 h of culture. A profound inhibition of cell growth was demonstrated after exposure to chelidonine starting at 5 μM concentration in all cancer cell lines. Homochelidonine application also increased the antiproliferative activity in a dose-dependent manner, but less than that of chelidonine at similar concentrations.
Both compounds showed a dramatic effect against A2780 cells, especially during the first 24 h. Dissimilar results were obtained The growth inhibitory effect of chelidonine and homochelidonine on A2780 ovarian carcinoma, A549 lung adenocarcinoma, HepG2 hepatocellular carcinoma, SK-BR-3 breast adenocarcinoma, MCF-7 breast adenocarcinoma, WI-38 and MRC-5 human fibroblast cells. Cells were treated for either 48 or 96 h and the sulforhodamine B protein biomass assay was employed to evaluate growth inhibition. Bars indicate mean ± SD, n = 3. * -significantly different from 0.1% DMSO mock treated control (P ≤ 0.05).
following chelidonine and homochelidonine exposure to MRC-5 and WI-38 cells. Non-cancer MRC-5 cells were less sensitive and, at concentrations of up to 50 µM, proliferated in an almost similar manner to the untreated controls. Treatment of WI-38 cells with homochelidonine led to delayed proliferation. Considering the antiproliferative activity of chelidonine in WI-38 cells, cell proliferation was also obviously inhibited in the initial stages when concentrations of 5 µM and higher were applied. However, with a longer interval of exposure, WI-38 cells exposed to chelidonine recovered from the inhibitory effect on cell proliferation (Figure 3 ).
Effects of chelidonine and homochelidonine on cell cycle progression
We have evaluated the effects of chelidonine and homochelidonine on the growth of human cancer and non-cancer cells. Treatment with either compound resulted in pronounced antiproliferative activity in A2780 cells, while in parallel experiments, the lowest growth inhibition was observed in MRC-5 cells. Since cell proliferation is generally controlled by the progression of three distinctive phases of the cell cycle, and cell cycle arrest is considered one of the most common causes of the inhibition of cell proliferation, we, therefore, determined whether the chelidonineAntiproliferative activity of chelidonine and homochelidonine Natural Product Communications Vol. 12 (9) 2017 1421 and homochelidonine-induced antiproliferative activities were accompanied by cell cycle perturbations. For this purpose, we selected human fibroblast MRC-5 and ovarian carcinoma A2780 cells. Exponentially proliferating cells were exposed to chelidonine and homochelidonine and the redistribution of the cells within the cell cycle phases was monitored over a period of 24 h after treatment. As seen in Figure 4A , chelidonine exposure resulted in an increased (P ≤ 0.05) accumulation of MRC-5 cells in the G2/M phase (5 µM -31.4 ± 0.3 %; 10 µM -41.6 ± 0.9 %; 20 µM -38.2 ± 0.9 %; 0.1% DMSO control 9.7 ± 2.2 %). At the same time, cells treated with chelidonine were significantly (P ≤ 0.05) decreased in G1-and S-phase cells compared with the negative control. Even if more than 50% of the MRC-5 cells remained in G1 when applying concentrations of up to 20 µM, chelidonine had an inhibitory effect on cell cycle progression, suppressing DNA replication in the Sphase and accumulating cells at G2/M. Minor changes were determined after homochelidonine application.
In homochelidonine-treated cells, cell cycle analysis revealed an increased proportion of cells in the G1 and G2/M phases and a decreased S-phase population. In variance thereto, the ovarian carcinoma A2780 cells treated with chelidonine were clearly more affected ( Figure 4B ). Results showed a pronounced G2/M arrest (5 µM -89.7 ± 0.5%; 10 µM -91.4 ± 0.7%; 20 µM -92.2 ± 0.6%; 0.1% DMSO control 16.6 ± 1.9 %) with a concomitant decrease in G1-and S-phase populations in A2780 cultures treated with chelidonine. Biphasic dose-depended G1 and G2/M cell cycle arrest was observed after treatment with homochelidonine. Homochelidonine exposure at the lower examined concentrations induced G1 cell cycle arrest (5 µM -59.6 ± 2.7%; 0.1% DMSO control 49.3 ± 2.7%). Application of homochelidonine in A2780 cells at higher concentrations of 10 µM and 20 µM showed predominant G2/M arrest (10 µM -32.4 ± 4.7%; 20 µM -84.2 ± 1.7%; 0.1% DMSO control 16.6 ± 1.9%). Considering the data obtained previously and in order to understand the cell cycle transitioning of the less affected growth inhibited MRC-5 cells, we further investigated the effect of chelidonine and homochelidonine treatment on cell cycle progression using the BrdU assay. The cells were pulse-labelled with BrdU before being treated with a dose of either 10 µM or 20 µM and then further incubated for the indicated time-periods ( Figure 5 ). Indeed, those cells that had been BrdUlabelled shortly before chelidonine treatment (S-phase cells) were already detected within the G2/M phase population 8 h later and seemed to be consolidated therein. Consistent with the accumulation of S-phase cells at the G2/M phase observed in the BrdU assay, the percentage of cells in the G1 phase of the cell cycle was reduced compared with the 0.1% DMSO control cells. More interestingly, 24 h after chelidonine treatment, the MRC-5 cells that had been in the G1 or G2/M phase when treatment began seemed to retain the ability for cell cycle transition (observe cycling cells negative for BrdU labelling in the histograms). Consistent with the data, 24 h after chelidonine treatment, the fractions of the BrdUpositive cells at G2/M were decreasing, indicating that BrdUpositive cells that had arrested in the G2/M phase had failed to progress further into mitosis (no cells recycled to the G1 phase as can be seen in 0.1% DMSO vehicle-treated cells). In conformity with cell cycle analysis, during homochelidonine treatment, a slowdown in cell proliferation was apparent (reduced amount of cycling BrdU-positive cells), but cell cycle accumulation was not extensive. The anthracycline, doxorubicin, which inhibits replication by acting on the topoisomerase II complex, was used as a reference compound. 
Apoptosis induction after chelidonine and homochelidonine treatment
To determine whether chelidonine and homochelidonine-mediated inhibition of MRC-5 and A2780 cell growth also involved a cytotoxic effect via apoptosis induction, we stained cells with Annexin V and PI after 24 h culture in either the absence or presence of the test compounds. Quantification of the Annexin V and PI assay shows that chelidonine significantly (P ≤ 0.05) downregulated the viability of MRC-5 cells at a dose of 20 µM. Interestingly, the flow cytometric bivariate analysis shown in Figure  6A revealed that only 0.7 ± 0.2% of MRC-5 cells exposed to chelidonine at 20 µM stained positive solely for Annexin V, and 21.3 ± 5.6% for both Annexin V and PI, representing early apoptotic and late apoptotic/necrotic cells, respectively. Homochelidonine treatment resulted in an insignificant increase in both subsets of Annexin V and PI labeled MRC-5 cells. Parallel experiments were performed with A2780 ovarian carcinoma cells ( Figure 6B ). Chelidonine revealed a profound dose-independent incidence of cell death in A2780 cells. In these experiments, chelidonine induced significant (P ≤ 0.05) early (Annexin V) and late (Annexin V and PI) apoptosis at concentrations from 5 µM to 20 µM. For example, A2780 cells treated with chelidonine at 20 µM showed an increase in Annexin V single positive and Annexin V/PI double positive populations (18.3 ± 2.4% and 11.8 ± 1.1%, respectively). Similarly, homochelidonine also revealed apoptosisinducing activity compared with sham treated control cells (2.7 ± 0.8% of early and 3.0 ± 1.5% of late apoptotic cells). However, at 20 µM, homochelidonine showed a slightly lower activity compared with chelidonine and fewer (9.9 ± 2.8%) apoptotic cells were recorded than after chelidonine treatment.
In accordance with the previous results, the highest reductions in cell numbers were particularly evident in A2780 cells that were also more sensitive to growth inhibition. On the other hand, the less sensitive MRC-5 cells, indicated by the sulforhodamine B assay and xCELLigence, appeared more resistant to cell death via apoptosis given the evaluated doses.
The effects of chelidonine and homochelidonine on mitotic arrest and microtubular structure
Profound G2/M cell cycle arrest led us to investigate the effect of chelidonine and homochelidonine on the mitotic arrest and microtubular structure of the evaluated cells. First we performed flow cytometry staining for Ser10 phosphorylated histone H3, a specific marker of mitosis, to determine whether chelidonine and homochelidonine induced cell cycle arrest specifically during mitosis or the G2 phase and whether the alkaloids for a particular cell type display a higher efficacy ( Figure 7 ). After 24 h of treatment with 10 µM concentrations of chelidonine and homochelidonine, the percentage of Ser10-phosphorylated histone histone H3-positive cells and the total biomass (total numbers of cells) determined by the sulforhodamine B assay in model cell lines. Guided by these observations, we investigated the effect of chelidonine and homochelidonine treatment on the pattern of distribution of microtubules (a critical cytoskeleton element), aiming to collect more information concerning the effect of the alkaloids on the proliferation and morphology of non-cancer MRC-5 and cancer A2780 cells. Immunofluorescence staining of microtubules with an anti-β-tubulin monoclonal antibody followed by DAPI counterstaining and epi-fluorescence imaging revealed that 0.1% DMSO mock-treated MRC-5 and A2780 cells had a typical array of interphase microtubules radiating from the nucleus. Similarly, as in sham-treated cells, chelidonine and homochelidonine-treated MRC-5 cells at 10 µM and 20 µM also maintained mostly intact microtubules ( Figure 8A ). In contrast, microtubule structures of A2780 cells were dramatically altered when chelidonine and homochelidonine were used in 10 µM and 20 µM concentrations. Both alkaloids caused abnormal aggregation of cellular microtubules, in which the interphase radial microtubule network appears bent and collapsed at the nuclear periphery ( Figure  8B ). These findings reinforce previous results concerning the sensitivity of MRC-5 and A2780 cells to the investigated alkaloids.
The effects of chelidonine on the viability and expression of proteins regulating cell cycle, cell survival and cell death
Chelidonine and homochelidonine revealed promising growth inhibitory activity against human cancer cell lines. However, generally, chelidonine exhibited greater potency than homochelidonine in sulforhodamine B and xCELLigence assays. In addition, chelidonine exerted little effect on healthy fibroblasts. Since antiproliferative and cytotoxic compounds are interesting only when their toxicity is higher for cancer cells than for noncancer ones, we further evaluated the effects of chelidonine exposure on the expression of cell cycle, cell survival and cell death associated proteins in A2780 and MRC-5 cells. First, cell viability was determined 24 h and 48 h after chelidonine treatment using trypan blue exclusion. The results consistently demonstrated dose and time-dependent reductions in cell numbers at 5 µM and 10 µM in A2780 cells. Moreover, as shown in Figure 9A , MRC-5 cells maintained an overall higher viability independently of concentrations and exposure times assayed.
Next, to investigate the mechanistic basis of the cytotoxic and cytostatic effects of chelidonine in A2780 and MRC-5 cells, we examined its effect on the expression of the key proteins involved in cell proliferation, cell survival and cell death by Western blot analysis. First, we examined checkpoint kinases 2 and 1 (Chk2 and Chk1) as key downstream checkpoint regulators activated by ataxia telangiectasia mutated (ATM) and ATM and Rad3 related (ATR) kinases, respectively. We found that the phospho-Chk2 (Thr68) levels were increased 24 h after chelidonine application at 5 and 10 µM whereas the phospho-Chk1 (Ser345) levels remained unchanged in A2780 cells. In contrast with the results obtained in A2780 cells, no significant changes in phospho-Chk2 (Thr68) and phospho-Chk1 (Ser345) levels were observed in MRC-5 cells. Furthermore, we found that chelidonine exposure in A2780 cells increased the amount of the p21
Cip1/Waf1 cyclin-dependent kinase inhibitor. When p21
Cip1/Waf1 increased, the Cdc25A phosphatase and Ser780 phosphorylated retinoblastoma protein (pRb) were slightly downregulated ( Figure 9B ). Subsequently, Western blotting was used to determine the changes in the content of the proteins related to mitogen-activated protein kinase (MAPK) pathways, with the results shown in Figure 9C . The effects of chelidonine on phosphorylation of ERK 1/2 (on threonine-202 and tyrosine-204 residues), JNK1/2 (on threonine-183 and tyrosine-185 residues), and p38 (on threonine-180 and tyrosine-182 residues) were analyzed in A2780 and MRC-5 cells after 24 h of treatment. JNK1/2 and p38 appear to play a role in the induction of apoptosis and are crucial for the proper maintenance of cell proliferation. Contrary thereto, ERK1/2 activation has been highlighted in cell survival and antiapoptotic activity. When evaluating A2780 cells, chelidonine treatment slightly altered the levels of phosphorylated ERK1/2. However, MRC-5 cells had clearly different reactions. There was a dose-dependent decrease in the amount of phosphorylated ERK1/2 and p38 under similar treatment conditions. In past research, chelidonine and homochelidonine have been studied for their potential usefulness as complementary and alternative medicine for many diseases. Both alkaloids show a number of different bioactivities and are well documented for their use in ethnopharmacological practice. In addition, recent cell culture studies show that chelidonine and also, to some extent, homochelidonine, have strong antiproliferative, cytotoxic and apoptosis-inducing capabilities [2c, 9]. For these reasons, Greater Celandine, containing chelidonine and homochelidonine as major constituents, may have the potential to generate a new target for drug discovery and development [2h, 10] . If so, then bioactivity could be counterbalanced by toxicity, which would limit the utility of chelidonine and homochelidonine-based drugs as therapeutics. Along with chelidonine and homochelidonine, C. majus also contains other alkaloids, the tumor cell line cytotoxicity of which has been repeatedly documented (e.g. sanguinarine and chelerythrine). These alkaloids usually provide more than a 50% inhibition at 10 µM [11a, b, c]. However, in contradiction to the reported alkaloid-induced cytotoxicity, other studies imply a protective activity of Greater Celandine extracts towards human health with documented choleretic, hepatoprotective, antiulcerogenic, analgesic, antispasmodic, anti-inflammatory and antimicrobial properties, as summarized by Gilca and colleagues [1] . Additionally, an increasing number of in vivo studies have suggested antitumor, antigenotoxic and hepatoprotective effects of the plant [2h], with negligible hepatotoxic effects in Wistar rats orally administrated with doses about 50 and 100 times higher than those generally used in humans [12] . Thus, since C. majus preparations such as dietary supplements continue to be formulated and used, the decreased cytotoxicity for non-cancer cells is one of the prerequisites for wide and safe use. Considering some inconsistent findings on this medicinal plant, we were interested to screen the potentially different bioactivity of chelidonine and homochelidonine against a mini-panel of human cancer and noncancer cells in vitro. Our study revealed profound growth inhibitory activity of chelidonine and homochelidonine against the human-derived cell lines A2780, A549, HepG2, SK-BR-3, MCF-7, MRC-5 and WI-38.
Moreover, both alkaloids exhibited greater potency against cancer cells (A2780, A549, HepG2, SK-BR-3 and MCF-7) than against non-cancerous ones (MRC-5 and WI-38) in the sulforhodamine B assay and during xCELLigence analysis. These findings are consistent with previous cell culture studies indicating that chelidonine, homochelidonine and C. majus crude ethanolic extract have a lower cytotoxicity against human primary cells [2c, 13] . As very recently reported, Deljanin and co-workers observed that C. majus extract showed a selective time-and dose-dependent increase in cytotoxicity in six human cancer cell lines (A549, H460, HCT 116, SW480, MDA-MB-231 and MCF-7) with IC 50 values ranging from 44.65 ± 3.66 to 213.35 ± 3.74 µg/mL. In the same study, the IC 50 value determined for human peripheral blood mononuclear cells (PBMCs) was above 500 μg/mL, which was the highest concentration tested [13] . A similar low sensitivity has been seen in PBMCs when treated with chelidonine and homochelidonine. When using the XTT tetrazolium salt assay, the IC 50 value of WI-38 cells, as well as PBMCs, treated with chelidonine and homochelidonine, exceeded 10 µM [2c]. Through a critical evaluation of the sulforhodamine B assay and xCELLigence real-time monitoring, chelidonine was found the most active in inhibiting in vitro cancer cell line proliferation with an advantage of certain specificity. In conformity with previous findings, the present study verified the potent inhibitory activity of chelidonine and homochelidonine for cell proliferation through inducing cell cycle arrest. Although chelidonine has been reported to induce cell cycle arrest before, for example, in monkey kidneys, Vero, Graham 293, HS27, WHCO5, HeLa [14a, 15] . In this study, however, we have provided for the first time a plausible mechanism of action, which involves the detailed profiling of the G2/M phase cell cycle arrest, quantification of cells arrested in mitosis and Western blot analysis of the key proteins involved in the maintenance of cell proliferation, cell survival or cell death. A2780 cells treated with chelidonine in a concentration range between 5 µM and 20 µM and stained by PI 24 h later were about 90% arrested in the G2/M phase of the cell cycle. At the same time, when compared with A2780 cells, exposure of MRC-5 cells to chelidonine with similar concentrations led to a decreased amount of G2/M phase-arrested cells, giving an approximately 40% accumulation. Thus, we followed the responses of BrdU pulselabeled cells (S-phase cells) within the total population of MRC-5 cells. In this assay, whereas S-phase cells (BrdU-positive cells) subjected to chelidonine treatment initially arrested in the G2/M phase, their chelidonine exposed counterparts from the G1 and G2/M phase retained the ability of cell cycle phase transitioning. Cell cycle analysis observations, showing that more than 50% of the MRC-5 cells remained in G1 when applying chelidonine at doses of up to 20 µM, are in conformity with BrdU-labeling. Twenty-four hours after treatment with chelidonine G1 and G2/M (BrdUnegative), MRC-5 cells regenerated the ability to make cell cycle transition. The data describing the cell cycle progressions completely halted at the G2/M phase observed in A2780 cells are in good accordance with previous results relating to PI staining and BrdU labeling in leukemic cells [2c] . Consistently, minor changes in the MRC-5 cell cycle distributions were evident following treatment with homochelidonine, while A2780 cells were clearly affected in a dose-dependent manner. Considering that one of the characteristics of cancer cells is the ability to avoid apoptosis through cell cycle arrest allowing the damage to be repaired before Antiproliferative activity of chelidonine and homochelidonine Natural Product Communications Vol. 12 (9) 2017 1427 undergoing mitosis [16] , and in order to gain further insight into the mechanisms responsible for the different bioactivity of chelidonine and homochelidonine in MRC-5 and A2780 cells, we measured the percentage of apoptotic cells stained with Annexin V and PI. Our flow cytometry results showed a reduced percentage of viable (negative for both probes) A2780 cells and an increase in both Annexin V single positive and Annexin V/PI double positive populations. In contrast, the effect of chelidonine and homochelidonine on MRC-5 cells using ascending doses of up to 20 µM was less significant. We observed a statistically significant elevation of cell death only at 20 µM, where 0.7 ± 0.2% of MRC-5 cells exposed to chelidonine stained solely positive for Annexin V and 21.3 ± 5.6% for both Annexin V and PI. Similar to our observations, the proapoptotic effect of chelidonine and/or homochelidonine has also been documented by other authors [2c, 9, 17] . Chelidonine was found to be a very potent microtubuledestabilizing agent in micromolar concentrations [14a, b] . Microtubules, which consist of polymers of α-and β-tubulins, play an important role throughout the regulation of chromosome separation in mitosis [14b] . Nowadays, increasing numbers of experimental works reported that the drugs that inhibit/promote tubulin assembly induce mitotic arrest at the early M-phase, resulting in a mitotic catastrophe for many types of cancer cells. However, the disruption of microtubule dynamics by administrated chemotherapeutic drugs also produces undesirable side effects on healthy proliferating cells [18] . In our study, bivariate flow cytometry analysis revealed an increased fraction of cells positive for an M-phase marker, the Ser10-phosphorylated form of histone H3, following chelidonine and homochelidonine treatment. Nonetheless, considering the correlation between the percentage of cells positive for Ser10-phosphorylated histone H3 and sensitivity to the antiproliferative activity of chelidonine and homochelidonine, no clear relationship was observed. To assess changes on the cellular microtubule network of MRC-5 and A2780 cells after 24-h treatment, we visualized microtubules and cell nuclei using a monoclonal antibody to β-tubulin and DAPI, respectively. Surprisingly enough, chelidonine and homochelidonine-treated MRC-5 cells maintained mostly intact microtubule distribution, while microtubule structures of A2780 cells were dramatically altered with dense bundles at the nuclear periphery. Our observations correlate well with recent findings that sanguinarine, chelerythrine and chelidonine effectively depolymerized the microtubules in human cervix carcinoma HeLa and osteosarcoma U2OS cells. Moreover, in the same set of experiments, these compounds exhibited a certain effect on the cellular actin filament network by reducing the mass of actin filaments [14b]. The upregulation and activation of protein targets involved directly in controlling the cell cycle, parallel with cell survival and cell death associated proteins, were evaluated by Western blotting. Twentyfour hour treatment of A2780 cells with chelidonine at 5 µM and 10 µM resulted in increased levels of phospho-Chk2 (Thr68), whereas phospho-Chk1 (Ser345) levels remained unchanged. As is well known, after DNA damage, both Chk1 and Chk2 kinases are required for Cdc25A proteasomal degradation/Cdc25C cytoplasmic sequestration resulting in cell cycle arrest at G1/S transition, Sphase or G2/M transition. Moreover, recent studies have highlighted roles for activated Chk1 and Chk2 kinases during cell cycle arrest before entry into mitosis. In this regard, Chk1 has been shown to be required for mitosis progression while Chk2 localizes to centrosomes in early mitosis, promotes mitotic spindle assembly, proper chromosome alignment and segregation [19a, b] . Although the phosphorylation of Chk2 at Thr68 is predominantly dependent on ATM kinase, emerging findings indicate that DNA dependent protein kinase catalytic subunit (DNA-PKcs) also participates in the phosphorylation of Chk2 at Thr68, at least when damage occurs during mitosis [20] . In A2780 cells, upon chelidonine exposure, increased accumulation of p21 Cip1/Waf1 was observed. As cell-cycle inhibitor p21
Cip1/Waf1 accumulates in cells in response to treatment, G1-and S-phase cyclin/cyclin dependent kinase complexes become inactivated, pRB is dephosphorylated, and cells arrest in either the G1-or S-phase [21] . Even if p21
Cip1/Waf1 preferentially mediates G1 cell cycle arrest, other reports also suggested a role for p21 Cip1/Waf1 in mediating G2/M cell cycle arrest [22] . While chelidonine-treated MRC-5 cells had no alternations in checkpoint-associated protein levels, there was a dose-dependent decrease in the amount of phosphorylated ERK1/2 and p38. In sham-treated controls, MRC-5 cells constitutively expressed detectable amounts of phosphorylated JNK1/2, ERK1/2 and p38, whereas A2780 cells constitutively expressed very little amounts of phosphorylated proteins (JNK1/2 and p38), or steady-state constitutive expression was absent (ERK1/2) altogether. Previous studies have found the antiapoptotic/prosurvival effects of ERK1/2 and proapoptotic effects of p38 and JNK1/2 [23] . Our Western blotting data are in agreement with previous studies demonstrating that MAPK subfamilies occur activated in human fibroblasts [24a, b] . In what concerns the effect of chelidonine on the level of phosphorylated ERK1/2, our results could be explained through evidenced G2-arresting and the proapoptotic activity of ERK1/2. It was observed that under such circumstances the inhibition of ERK1/2 activation attenuates apoptosis or G2/M arrest induced by etoposide, adriamycin, platinum compounds and UV radiation [25] .
In summary, the present study provides a plausible insight into the chelidonine and homochelidonine-induced inhibition of cell growth in vitro in both human cancer and non-cancer cells. Depending on the cell type, we have taken into consideration the antitumor potential of C. majus alkaloids given cytostatic and cytotoxic activity as well as the diverse range of beneficial biological properties, while cell proliferation and viability remained virtually unaffected. Moreover, our study identified chelidonineinduced alternations in the cell cycle checkpoints and MAPK signaling pathways as a basis for the elucidation of the yet largely unknown molecular mechanisms in human cells. In the future, efforts should be made to extrapolate these findings to animal models.
Experimental

Cell cultures and culture conditions:
The experiments were carried out with the MRC-5, WI-38 (both primary human lung fibroblast), A2780 (ovarian carcinoma), A549 (lung adenocarcinoma), HepG2 (hepatocellular carcinoma), SK-BR-3 and MCF-7 (both breast adenocarcinoma) cells from the European Collection of Cell Cultures (ECACC, Salisbury, UK). MRC-5 and WI-38 cells were propagated in Minimum Essential Medium Eagle with Earle's BSS (Lonza Group, Basel, Switzerland) supplemented with 10%, v/v, fetal bovine serum, 2 mM L-glutamine, 10 µL/mL MEM NonEssential Amino Acids, 50 µg/mL penicillin and 50 µg/mL streptomycin (all reagents from Life Technologies, Grand Island, NY, USA). A2780 cells were propagated in a RPMI 1640 medium supplemented with 10%, v/v, fetal bovine serum, 2 mM Lglutamine, 1 mM pyruvate, 10 mM HEPES, MEM Non-Essential Amino Acids 10 µL/mL, 50 µg/mL penicillin and 50 µg/mL streptomycin (all reagents from Life Technologies, Grand Island, NY, USA). A549 cells were cultured in Minimum Essential Medium Eagle with L-glutamine and sodium bicarbonate (SigmaAldrich, St. Louis, MO, USA) in the presence of 10%, v/v, fetal calf serum, 1 mM pyruvate, 10 mM HEPES, 50 µg/mL penicillin and 50 µg/mL streptomycin (all supplements from Life Technologies, Grand Island, NY, USA). SK-BR-3 cells were cultured in a McCoy's 5A medium (Life Technologies, Grand Island, NY, USA) supplemented with 10%, v/v, fetal calf serum and 50 µg/mL penicillin and 50 µg/mL streptomycin (all reagents and supplements from Life Technologies, USA). MCF-7 cells were maintained in Minimum Essential Medium Eagle with L-glutamine and sodium bicarbonate (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10%, v/v, fetal calf serum, 1 µg/mL insulin, 50 µg/mL penicillin and 50 µg/mL streptomycin (all reagents from Life Technologies, Grand Island, NY, USA). HepG2 was propagated in DMEM -a high glucose medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10%, v/v, fetal bovine serum, 2 mM Lglutamine, 1 mM pyruvate, 10 mM HEPES, 10 µL/mL MEM NonEssential Amino Acids, 50 µg/mL penicillin and 50 µg/mL streptomycin (all reagents from Life Technologies, Grand Island, NY, USA). The cell cultures were maintained at 37°C in a humidified incubator in an atmosphere of 5% CO 2 -95% air. The cultures were split every third day. The CASY Cell Counter and Analyzer (Roche, Basel, Switzerland) was used for basic quality control of the cell culture system, for evaluating cell numbers, cell viability and cell debris. Cells in the maximum range of 10 passages for primary cell lines (MRC-5 and WI-38), or in the maximum range of 20 passages for cancer cell lines (A2780, A549, HepG2, SK-BR-3 and MCF-7) and in an exponential growth phase were used for this study. 
Antiproliferation sulforhodamine B assay:
The growth inhibition effects of chelidonine and homochelidonine against a mini-panel of non-cancer and cancer cells were determined using a sulforhodamine B (SRB) assay, which is based on the measurement of cellular protein content. Briefly, the previously optimized number of cells was plated in a complete culture medium in each well of the 24-well plate and incubated overnight for attachment; the medium was then replaced with either a control medium or with a medium containing chelidonine or homochelidonine at 5, 10, or 20 µM. Wells containing only a complete medium without cells were used as a blank sample. At the end of the experiment, the cells were fixed with 10% trichloroacetic acid, w/v, and incubated for 1 h at 4°C. The plates were then washed with deionized water thrice and air dried before subsequent incubation at room temperature for 30 min with SRB dye at 0.4%, w/v, in 1% acetic acid, v/v. Unbound dye was removed by washing with 1% acetic acid, v/v, thrice and the plates were air dried. Tris base (10 mM) was then added to the wells to solubilize the bound SRB dye, and the plates were then read at 565 nm using a multiwell microplate reader, specifically Tecan Infinite M200 (Tecan Group Ltd., Männedorf, Switzerland). The percentage of growth inhibition was calculated using the following formula: (%) growth = (A565sample -A565blank) / (A565control -A565blank) x 100, where A565 is the absorbance of solubilized SRB dye measured at 565 nm [26] .
xCELLigence: The xCELLigence system (Roche, Basel, Switzerland and ACEA Biosciences, San Diego, CA, USA) was used to monitor cell adhesion, proliferation and cytotoxicity. The xCELLigence system was connected and tested by Resistor Plate before the RTCA Single Plate station was placed inside the incubator at 37°C and 5% CO 2 . First, the optimal seeding concentration for proliferation experiments was optimized for each cell line. After seeding, the respective number of cells in 190 µL of medium per well of the E-plate 96, the proliferation, attachment and spreading of the cells were monitored every 30 min by the xCELLigence system. Approximately 24 h after seeding, when the cells were in the log growth phase, the cells were exposed in triplicates to 10 µL sterile deionized water containing either chelidonine or homochelidonine to obtain final concentrations of 1-50 μM. Controls received sterile deionized water + DMSO with a final concentration of 0.1%, v/v. Cells treated with 5%, v/v, DMSO were used as positive control. Growth curves were normalized to the time point of treatment. Evaluations were performed using xCELLigence 1.2.1 software (Roche, Basel, Switzerland and ACEA Biosciences, San Diego, CA, USA).
Viability: Cell viability of A2780 and MRC-5 cells was determined 24 and 48 h after treatment with 5 and 10 μM of chelidonine. Cell membrane integrity was determined using the Trypan blue exclusion technique by mixing 10 μL of 0.4% Trypan blue and 10 μL of cell suspension. Cell counts were carried out using a Bürker chamber and Nikon Eclipse E200 light microscope (Nikon, Tokyo, Japan). , and the property of propidium iodide (PI) to enter cells with damaged cell membranes and to bind to DNA. Measurement was performed immediately using a CyAn (Beckman Coulter, Miami, FL, USA) flow cytometer. Listmode data were analyzed using Kaluza Analysis 1.3 software (Beckman Coulter, Miami, FL, USA).
Analysis of apoptosis:
Cell cycle distribution and internucleosomal DNA fragmentation analysis: Where cell cycle distribution analysis is concerned, the cells were washed with ice cold PBS and fixed with 70%, v/v, ethanol. In order to detect low molecular-weight fragments of DNA, the cells were incubated for 5 min at room temperature in a buffer (192 mL 0.2 M Na 2 HPO 4 + 8 mL of 0.1 M citric acid, pH 7.8) and then labeled with propidium iodide in Vindelov's solution for 1 h at 37ºC. The DNA content was determined using a CyAn flow cytometer (Beckman Coulter, Miami, FL, USA) with an excitation wave length of 488 nm. The data were analyzed using Multicycle AV software (Phoenix Flow Systems, San Diego, CA, USA).
Enumeration of mitotic cells, including measurement of histone H3 phosphorylated at Ser10 and DNA content: Histone H3 is phosphorylated at Ser10 when cells enter the mitotic phase and remains unphosphorylated in the other phases of the cell cycle. To determine the number of mitotic cells, cells treated with 10 μM of chelidonine and homochelidonine were fixed and permeabilized by adding ice-cold 100%, v/v, methanol. Following overnight incubation, the cells were washed with a PBS-0.5%, w/v, BSA solution and subsequently stained with the Alexa Fluor 488-conjugated anti-pSer10-histone H3 (Cell Signaling Technology, Beverly, MA, USA) antibody diluted with a PBS-0.5% BSA solution in accordance with the manufacturer's instructions. Cells were incubated with agitation for 60 min at room temperature in the dark. Finally, the cells were washed twice with the PBS-0.5%, w/v, BSA solution and resuspended in a PI staining solution (BD Biosciences, San Jose, CA, USA) at a final volume of 500 µL. All samples were immediately analyzed by a CyAn flow cytometer and the data were plotted using Kaluza Analysis 1.3 software (both from Beckman Coulter, Miami, FL, USA).
BrdU incorporation and DNA content: Cells were pulse-labeled with 10 µM of 5-bromo-2′-deoxyuridine (BrdU) for 30 min prior to assay. After BrdU, pulse cells were washed twice with PBS, resuspended in a fresh medium and then treated by sham-(DMSO control), chelidonine or homochelidonine. At various time points post-treatment, the cells were harvested and fixed in cold 70%, v/v, ethanol. The cells were then stained for both DNA content and BrdU incorporation using the acid denaturation method. Briefly, the cells were washed in a TBS-0.5%, w/v, BSA solution, denatured by freshly made 2 M HCl and resuspended in 0.1 M sodium metaborate to neutralize HCl. After subsequent washing in TBS-0.5%, w/v, BSA, a fluorescein isothiocyanate (FITC)-conjugated mouse anti-BrdU monoclonal antibody (BD Biosciences, San Jose, CA, USA) for BrdU detection was used and, finally, cell pellets were resuspended in a TBS-0.5%, w/v, BSA solution containing propidium iodide (PI) at 10 µg/mL and RNase A at 0.5 mg/mL for DNA content staining. All samples were immediately analyzed by a CyAn flow cytometer and the data were plotted using Kaluza Analysis 1.3 software (both from Beckman Coulter, Miami, FL, USA).
Epi-fluorescence microscopy: For each condition, 250, 000 cells were seeded in 2-well chamber slides SPL (SPL Life Sciences, Korea). After seeding (usually 24 h later), the spent medium was replaced with fresh medium and the cells were treated with chelidonine and homochelidonine at 10 and 20 µM. Following 24-h treatment, the cells were fixed with 4% freshly prepared paraformaldehyde for 10 min at room temperature, washed with PBS, permeabilized in 0.2% Triton X-100/PBS for 15 min at room temperature and washed with PBS (all reagents from SigmaAldrich, St. Louis, MO, USA). Before incubation with the primary antibody (overnight at 4°C), the cells were incubated with 7%, v/v, heat inactivated fetal calf serum + 2%, w/v, bovine serum albumin in PBS for 30 min at room temperature. Mouse monoclonal anti-β-tubulin (Life Technologies, Grand Island, NY, USA) was used for β-tubulin detection. For the secondary antibody, the affinity pure donkey anti-mouse-TRITC-conjugated antibody was purchased from the Jackson ImmunoResearch Laboratories (West Grove, PA, USA). The secondary antibody was applied to each slide (after preincubation with 5.5%, v/v, donkey serum in PBS for 30 min at room temperature), incubated for 1 h in the dark and washed (3 × 5 min) with PBS. The nuclei were counterstained with 100 µL of 4',6-diamidino-2-phenylindole (DAPI) at 1 µg/mL for 30 min. After the last 2 washes with PBS, the slides were mounted with an antifading ProLong® Gold mounting medium (Life Technologies, Grand Island, NY, USA). Images of all the examined slides were obtained by a Nikon epi-fluorescence microscope system -Eclipse 80i; the exposure time and dynamic range of the camera in all of the channels were adjusted to the same values for all of the slides to portray quantitatively comparable images. Images were further processed and merged using NIS-Elements Advanced Research 4.13 (instrument and software from Nikon, Tokyo, Japan).
Western blot analysis: Whole-cell lysates (Cell Lysis Buffer, Cell Signaling Technology, Danvers, MA, USA) were prepared 24 h following treatment of A2780 and MRC-5 cells with chelidonine and homochelidonine. Cells treated with 0.1% DMSO were used as negative control. Quantification of the protein content was performed using the BCA assay (Sigma-Aldrich, St. Louis, MO, USA). The lysates (20 μg purified protein) were loaded into each lane of a polyacrylamide gel. After electrophoretic separation, the proteins were transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). Non-specific binding of the membranes was blocked for 1 h in a Tris-buffered saline containing 0.05% Tween 20 (TBS) and 5%, w/v, non-fat dry milk. The membranes were washed in TBS. Incubation with a primary antibody against specific antigens (p21, β-actin -Sigma-Aldrich, St. Louis, MO, USA; Mre11, Chk1, Chk1_serine 345, Chk2, Chk2_ threonine 68, ERK 1/2_threonine 202 and tyrosine 204, JNK1/2_threonine 183 and tyrosine 185, p38_threonine 180 and tyrosine 182, Cdc25A, Rb_serine 780 -Cell Signaling, Danvers, MA, USA) was performed at 4°C overnight. The following day the membranes were washed 5-times with TBS, each time for 5 min, and once with TBS, for 10 min, and then incubated with an appropriate secondary antibody (DakoCytomation, Glostrup, Denmark) for 1 h at room temperature. Band detection was performed using a chemiluminiscence detection kit (Roche, Basel, Switzerland). To ensure equal protein loading, each membrane was reprobed and β-actin was detected.
Statistical analysis:
The descriptive statistics of the results were calculated and the charts were made in either Microsoft Office Excel 2010 (Microsoft, Redmond, WA, USA) or GraphPad Prism 5 biostatistics (GraphPad Software, La Jolla, CA, USA). In this study, all the values were expressed as arithmetic means with SD of triplicates, unless otherwise noted. The significant differences between the groups were analyzed using the Student's t-test.
